PENN AVENUE PARTNERS

Lobbying for ALKERMES, INC. · Pharmaceutical manufacturing and biopharmaceutical company.

Filing 4th Quarter - Report

4th Quarter (Oct 1 - Dec 31) 2025 · Massachusetts · House · Senate · $80,000.00 income · posted Jan 9, 2026

Lobbying activity 1

Pharmacy

Regulatory and legislative issues impacting Alkermes. Appropriations.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.